Eran Orr: Virtual Reality Coming to ADHD


A virtual reality platform could enable ADHD patients to improve cognitive functioning.

The need to leverage new technology may have never been greater in treating attention deficit/hyperactivity disorder (ADHD), especially during the coronavirus disease 2019 (COVID-19) pandemic.

Virtual reality experiences have the opportunity to really help children who are suffering from ADHD, presenting a virtual world that can help deal with some of the symptoms of the disorder.

Recently, XRHealth unveiled a new ADHD virtual reality system aimed at improving well-known ADHD cognitive functioning, including attention, impulsivity, and higher and more complex thinking functions such as initiating, organizing, planning, and fully executing daily tasks.

In the new VR system, each user is monitored for progress based on sustained focus while distractions are present.

The new system is based on the brain’s ability to restructure itself in attempt to overcome existing challenges, referred to as the brain’s plasticity principle.

Clinicians will also have the ability to create, monitor, and adjust the training process at every step within the training system.

The system contains a number of core focuses, including motor activation, a visual and auditory experience that mimics real life activity to improve motor movement, and integrated eye tracking technology.

In an interview with HCPLive®, Evan Orr, Founder and CEO of XRHealth, explained how the new virtual reality platform works and why ADHD lends itself to a virtual reality solution.

Related Videos
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
Daniel Greer, PharmD: Reduction in Rehospitalizations with Antipsychotic Injections for Schizophrenia
© 2024 MJH Life Sciences

All rights reserved.